Forest Services
Introduction: Semaglutide Usage and Emerging Self-Medication Trends
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and obesity management, has witnessed a rapid rise in prescriptions in India since 2021. According to the Central Drugs Standard Control Organization (CDSCO), semaglutide prescriptions increased by over 150% between 2021 and 2023. Concurrently, an Indian Express survey (2024) revealed that approximately 30% of semaglutide users self-medicate without physician consultation, exposing gaps in drug regulation and public health safety. This surge coincides with India’s obesity prevalence rising from 12.6% in 2015 to 19.3% in 2022 (NFHS-5), driving demand for anti-obesity pharmacotherapy.
UPSC Relevance
- GS Paper 2: Health sector governance, drug regulation, public health challenges
- GS Paper 3: Economic impact of pharmaceutical markets, health expenditure
- Essay: Drug regulation and public health safety in India
Legal Framework Governing Semaglutide and Prescription Drugs
The Drugs and Cosmetics Act, 1940 regulates semaglutide as a prescription drug under Sections 18 and 27, mandating its sale only on valid prescriptions. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 prohibits misleading advertisements that could encourage self-medication. The Epidemic Diseases Act, 1897 empowers authorities to impose restrictions during health emergencies but does not directly address drug misuse. The Supreme Court ruling in Union of India v. Mohd. Rafique (2019) underscored the necessity of strict enforcement of drug laws to prevent unauthorized sales. Despite these provisions, enforcement remains fragmented, especially with the rise of e-pharmacies and online sales platforms.
- Section 18, Drugs and Cosmetics Act: Regulates sale of prescription drugs; requires prescription for Schedule H and H1 drugs.
- Section 27, Drugs and Cosmetics Act: Prohibits sale without prescription; penalizes violations.
- Drugs and Magic Remedies Act: Bans advertisements promoting self-medication or false claims.
- Supreme Court directives: Emphasize monitoring and penalizing unauthorized drug sales.
Economic Impact of Semaglutide Boom and Self-Medication
India’s anti-obesity drug market, including semaglutide, is projected to grow at a compound annual growth rate (CAGR) of 12.5%, reaching USD 1.2 billion by 2025 (Frost & Sullivan, 2023). However, self-medication inflates out-of-pocket health expenses, which already constitute 62% of total health expenditure (National Health Accounts, 2019-20). India’s dependence on China for over 70% of semaglutide raw materials (Pharma Export Promotion Council, 2023) exposes supply chain vulnerabilities. Unregulated use also risks adverse drug reactions (ADRs), increasing the cost burden on public health infrastructure due to hospitalizations and treatment of complications.
- Anti-obesity drug market size: USD 1.2 billion by 2025.
- Out-of-pocket health expenditure: 62% of total health spending.
- Import dependence: >70% raw materials from China.
- Adverse drug reactions linked to semaglutide increased by 40% in 2023 (Pharmacovigilance Programme of India).
Institutional Roles and Challenges in Regulation
The CDSCO serves as the national regulatory authority responsible for drug approval, surveillance, and enforcement. However, its capacity is stretched by the rapid growth of e-pharmacies and OTC sales. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) monitors trade compliance but has limited regulatory authority. The National Institute of Nutrition (NIN) provides research inputs on obesity trends but lacks enforcement powers. The Food Safety and Standards Authority of India (FSSAI) regulates dietary supplements, which are often confused with pharmaceutical drugs, complicating enforcement. The Ministry of Health and Family Welfare (MoHFW) formulates policies but coordination gaps persist between central and state agencies.
- CDSCO: Drug approval, post-marketing surveillance, enforcement.
- Pharmexcil: Oversees pharmaceutical trade, import-export data.
- NIN: Research on obesity and metabolic disorders.
- FSSAI: Regulates dietary supplements, not pharmaceuticals.
- MoHFW: Policy formulation, inter-agency coordination.
Data on Semaglutide Use and Self-Medication in India
Data indicates a sharp rise in semaglutide consumption and associated risks. CDSCO reported a 150% increase in prescriptions from 2021 to 2023. The Indian Express survey (2024) found 30% of users self-medicate, bypassing medical supervision. The Pharmacovigilance Programme of India recorded a 40% rise in ADR reports linked to semaglutide in 2023 compared to 2022. Self-medication accounts for 68% of total drug consumption in India, the highest among BRICS nations (WHO Global Report on Medicines Use, 2022), indicating systemic regulatory weaknesses.
- Semaglutide prescriptions increased by 150% (2021-2023).
- 30% of users self-medicate without doctor consultation.
- 40% rise in adverse drug reactions linked to semaglutide (2023 vs. 2022).
- Self-medication: 68% of total drug consumption in India.
Comparative Analysis: India vs United States on Semaglutide Regulation
| Aspect | India | United States |
|---|---|---|
| Regulatory Authority | CDSCO | Food and Drug Administration (FDA) |
| Legal Framework | Drugs and Cosmetics Act, 1940; fragmented enforcement | Food, Drug, and Cosmetic Act (FDCA); strict enforcement |
| Prescription Status | Prescription drug but OTC availability common | Strictly prescription-only |
| Post-Marketing Surveillance | Limited, under-reporting of adverse events | Robust; 25% reduction in adverse events over 3 years |
| Self-Medication Prevalence | High (30% semaglutide users) | Low due to strict control |
Regulatory Gaps and Public Health Implications
India lacks an integrated framework linking prescription drug regulation with digital health platforms and e-pharmacies. The Drugs and Cosmetics Act and its amendments do not adequately address online drug sales or real-time adverse event monitoring. Poor ADR reporting and enforcement gaps enable widespread self-medication, increasing risks of complications and antibiotic resistance. The public health system faces growing pressure from adverse reactions and misuse, undermining efforts to control obesity and diabetes effectively.
- No comprehensive regulation of e-pharmacies and digital prescriptions.
- Inadequate adverse drug reaction reporting mechanisms.
- Enforcement challenges in curbing OTC sales of prescription drugs.
- Public health burden from unsupervised drug use and complications.
Way Forward: Strengthening Drug Regulation and Public Health Safety
- Amend the Drugs and Cosmetics Act to explicitly regulate e-pharmacies and digital prescriptions.
- Enhance capacity of CDSCO for real-time monitoring and enforcement.
- Implement mandatory ADR reporting linked to semaglutide and other high-risk drugs.
- Launch public awareness campaigns on risks of self-medication and importance of medical supervision.
- Coordinate between MoHFW, CDSCO, FSSAI, and state authorities for unified action.
- Promote domestic production of semaglutide raw materials to reduce import dependence.
- The Drugs and Cosmetics Act, 1940 prohibits sale of semaglutide without prescription.
- The Food Safety and Standards Authority of India (FSSAI) regulates semaglutide as a dietary supplement.
- The Drugs and Magic Remedies Act bans misleading advertisements promoting self-medication.
Which of the above statements is/are correct?
- Self-medication accounts for over 60% of total drug consumption in India.
- India has a comprehensive legal framework integrating e-pharmacy regulation with prescription drug laws.
- Adverse drug reaction reports linked to semaglutide increased by 40% in 2023 compared to 2022.
Which of the above statements is/are correct?
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 (Health and Social Welfare), Paper 3 (Science and Technology)
- Jharkhand Angle: Rising obesity rates in Jharkhand mirror national trends, increasing demand for anti-obesity drugs including semaglutide; local healthcare infrastructure faces challenges in regulating drug sales and managing ADRs.
- Mains Pointer: Frame answers highlighting state-level enforcement gaps, need for awareness campaigns in tribal and rural areas, and coordination between state drug authorities and CDSCO.
What is semaglutide and its approved uses?
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes management and obesity treatment. It helps regulate blood sugar and reduces appetite, aiding weight loss.
Which Act regulates the sale of semaglutide in India?
The Drugs and Cosmetics Act, 1940 regulates semaglutide as a prescription drug under Sections 18 and 27, mandating sale only on valid prescriptions.
Why is self-medication with semaglutide a concern?
Self-medication risks include incorrect dosing, adverse drug reactions, drug interactions, and delayed medical supervision, leading to increased morbidity and healthcare costs.
How does India’s semaglutide regulation compare with the United States?
In the US, semaglutide is strictly prescription-only under the FDCA enforced by the FDA, with robust post-marketing surveillance reducing adverse events. India’s enforcement is fragmented, with widespread OTC availability and higher misuse.
What institutional gaps exist in India’s drug regulation system?
India lacks integrated regulation of e-pharmacies, real-time adverse event monitoring, and coordination between central and state agencies, limiting effective control of self-medication and drug safety.